{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:11:22Z","timestamp":1793272282171,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014620","name":"Micropalaeontological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.03.019","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:44:28Z","timestamp":1776339868000},"page":"1341-1350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efgartigimod in Sj\u00f6gren\u2019s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-3655","authenticated-orcid":false,"given":"Isabelle","family":"Peene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5682-6085","authenticated-orcid":false,"given":"Gwenny M","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-7640","authenticated-orcid":false,"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans G M","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"De Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Achten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-3364","authenticated-orcid":false,"given":"Julie","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Teperov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-4273","authenticated-orcid":false,"given":"Paul","family":"Meyvisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Fardipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janki","family":"Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-974X","authenticated-orcid":false,"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-9785","authenticated-orcid":false,"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2026.03.019_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren's syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ard.2026.03.019_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1003054","article-title":"Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sj\u00f6gren's syndrome: a critical review","volume":"13","author":"Vilchez-Oya","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ard.2026.03.019_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.autrev.2010.09.001","article-title":"The meaning of anti-Ro and anti-La antibodies in primary Sj\u00f6gren's syndrome","volume":"10","author":"Hernandez-Molina","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.ard.2026.03.019_bib0004","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren's syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"issue":"5","key":"10.1016\/j.ard.2026.03.019_bib0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/joim.13032","article-title":"Wahren-Herlenius M. Environmental factors in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome","volume":"287","author":"Bjork","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.ard.2026.03.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.ard.2026.03.019_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sj\u00f6gren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.019_bib0008","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/rheumatology\/key360","article-title":"Wahren-Herlenius M. Innate immunity and interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Bodewes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ard.2026.03.019_bib0009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ard.2026.03.019_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"17","key":"10.1016\/j.ard.2026.03.019_bib0011","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/jcm11175227","article-title":"Sj\u00f6gren syndrome: new insights in the pathogenesis and role of nuclear medicine","volume":"11","author":"Kelly","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.ard.2026.03.019_bib0012","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2026.03.019_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100138","article-title":"Autoantibodies in Sj\u00f6gren's syndrome and its classification criteria","volume":"5","author":"Veenbergen","year":"2022","journal-title":"J Transl Autoimmun"},{"issue":"5","key":"10.1016\/j.ard.2026.03.019_bib0014","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ard.2026.03.019_bib0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sj\u00f6gren's syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ard.2026.03.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"10.1016\/j.ard.2026.03.019_bib0017","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/acr.24597","article-title":"Antibodies to both Ro52 and Ro60 for identifying Sj\u00f6gren's syndrome patients best suited for clinical trials of disease-modifying therapies","volume":"74","author":"Armagan","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.ard.2026.03.019_bib0018","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/diagnostics10070478","article-title":"A broader perspective on anti-Ro antibodies and their fetal consequences-a case report and literature review","volume":"10","author":"Popescu","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ard.2026.03.019_bib0019","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3389\/fimmu.2017.01384","article-title":"B cells are indispensable for a novel mouse model of primary Sj\u00f6gren's syndrome","volume":"8","author":"Zheng","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ard.2026.03.019_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.03.019_bib0021","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/annrheumdis-2014-206683","article-title":"The SSB-positive\/SSA-negative antibody profile is not associated with key phenotypic features of Sj\u00f6gren\u2019s syndrome","volume":"74","author":"Baer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.03.019_bib0022","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.ard.2025.05.004","volume":"84","author":"Bowman","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3-4","key":"10.1016\/j.ard.2026.03.019_bib0023","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaut.2009.09.009","article-title":"Sj\u00f6gren syndrome: advances in the pathogenesis from animal models","volume":"33","author":"Chiorini","year":"2009","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.ard.2026.03.019_bib0024","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for Sj\u00f6gren's disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"15","key":"10.1016\/j.ard.2026.03.019_bib0025","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell Mol Life Sci"},{"issue":"24","key":"10.1016\/j.ard.2026.03.019_bib0026","doi-asserted-by":"crossref","first-page":"17228","DOI":"10.1074\/jbc.M113.522565","article-title":"Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies","volume":"289","author":"Sand","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ard.2026.03.019_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ard.2026.03.019_bib0028","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.ard.2026.03.019_bib0029","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.ard.2026.03.019_bib0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ard.2026.03.019_bib0031","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ard.2026.03.019_bib0032","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1744666X.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.ard.2026.03.019_bib0033","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of relevant endpoints for Sj\u00f6gren's syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2026.03.019_bib0034","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren's syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.03.019_bib0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","article-title":"A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren's syndrome international registry","volume":"149","author":"Whitcher","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"10518","key":"10.1016\/j.ard.2026.03.019_bib0036","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0140-6736(25)01430-8","article-title":"Efficacy and safety of nipocalimab in patients with moderate-to-severe Sj\u00f6gren\u2019s disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial","volume":"406","author":"Noaiseh","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ard.2026.03.019_bib0037","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2665-9913(20)30220-4","article-title":"Advances in treatments for Sj\u00f6gren\u2019s syndrome: the glass is half full","volume":"2","author":"Felten","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.03.019_bib0038","first-page":"283","article-title":"Ten years of the ESSDAI: is it fit for purpose?","volume":"38 Suppl 126","author":"de Wolff","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.019_bib0039","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ard.2026.03.019_bib0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ard.2026.03.019_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"issue":"10413","key":"10.1016\/j.ard.2026.03.019_bib0042","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ard.2026.03.019_bib0043","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ard.2026.03.019_bib0044","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:39:09Z","timestamp":1785901149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0003496726002050"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.019","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efgartigimod in Sj\u00f6gren\u2019s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}